FDA sends "courtesy letters" to three zinc lozenge makers for cold claims.
This article was originally published in The Tan Sheet
Executive Summary
THREE ZINC LOZENGE MAKERS RECEIVE FDA "COURTESY LETTERS" stating that the products' structure/function claims to treat the common cold are drug claims. The FD&C Act "makes clear that a statement included in labeling...may not claim to diagnose, mitigate, treat, cure or prevent a specific disease or class of diseases," FDA points out in its May 22 letter to Rx Vitamins. "The statement that you are making for Zinc Lozenges suggests that this product is intended for at least one of these purposes in that it claims to reduce the duration of symptoms caused by the common cold," the agency declares
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.